Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment
Molecules · 2023
DOI: 10.3390/molecules28073047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Silvia Gobbi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Flavonoids, Drug Design. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research.
Abstract (Originalsprache)
Despite the significant outcomes attained by scientific research, breast cancer (BC) still represents the second leading cause of death in women. Estrogen receptor-positive (ER+) BC accounts for the majority of diagnosed BCs, highlighting the disruption of estrogenic signalling as target for first-line treatment. This goal is presently pursued by inhibiting aromatase (AR) enzyme or by modulating Estrogen Receptor (ER) α. An appealing strategy for fighting BC and reducing side effects and resistance issues may lie in the design of multifunctional compounds able to simultaneously target AR and ER. In this paper, previously reported flavonoid-related potent AR inhibitors were suitably modified with the aim of also targeting ERα. As a result, homoisoflavone derivatives 3b and 4a emerged as well-balanced submicromolar dual acting compounds. An extensive computational study was then performed to gain insights into the interactions the best compounds established with the two targets. This study highlighted the feasibility of switching from single-target compounds to balanced dual-acting agents, confirming that a multi-target approach may represent a valid therapeutic option to counteract ER+ BC. The homoisoflavone core emerged as a valuable natural-inspired scaffold for the design of multifunctional compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
- Molecular Pharmacology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Via Amadeo 42, 20113 Milano, Italy.
- National Research Council of Italy Institute of Materials (CNR-IOM) c/o SISSA, Via Bonomea 265, 34136 Trieste, Italy.
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Viale delle Scienze, 90128 Palermo, Italy.
ORCID-Profile: Silvia Gobbi, Silvia Martini, Riccardo Rozza, Angelo Spinello, Angela Rampa, Federica Belluti, Nadia Zaffaroni, Alessandra Magistrato, Alessandra Bisi
Förderung
- Italian Association for Cancer Research
Zitieren
APA
Gobbi, S., Martini, S., Rozza, R., Spinello, A., Caciolla, J., Rampa, A., Belluti, F., Zaffaroni, N., Magistrato, A., & Bisi, A. (2023). Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment. Molecules. https://doi.org/10.3390/molecules28073047
Vancouver
Gobbi S, Martini S, Rozza R, Spinello A, Caciolla J, Rampa A, et al. Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment. Molecules. 2023. doi:10.3390/molecules28073047
BibTeX
@article{Gobbi2023,
author = {Gobbi, Silvia and Martini, Silvia and Rozza, Riccardo and Spinello, Angelo and Caciolla, Jessica and Rampa, Angela and Belluti, Federica and Zaffaroni, Nadia and Magistrato, Alessandra and Bisi, Alessandra},
title = {Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28073047}
}
EUVIMED